美股新聞 標題聯播 · 近 24 小時 337 則 · 29 個來源 · 最新 9/20 04:53
本站只列標題、來源、時間與原文連結,不重製內文;著作權屬原媒體與原作者。新聞稿通路(PR Newswire、Business Wire、GlobeNewswire)是公司自己發的,屬第一手;媒體是轉述。
全部 · TSHA近 30 天 2 則 · 第 1 / 1 頁
- These 3 Risky Stocks Could Be Sitting on 100% Upside
- Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
- Taysha Gene Therapies (TSHA) Q2 2026 Earnings Call
- Taysha Gene Therapies (TSHA) After Rett Trial Progress And Catalent Expansion Is The Undervalued Case Stronger
- Taysha Gene Therapies, Inc. Q2 2026 Earnings Call Summary
- Taysha Gene Therapies Inc (TSHA) (Q2 2026) Earnings Call Highlights: Rett Syndrome Program ...
- Taysha Gene Therapies Q2 Earnings Call Highlights
- Taysha Gene Therapies Reports Second Quarter 2026 Financial Results and Provides Corporate Update
- Taysha Gene Therapies to Release Second Quarter 2026 Financial Results and Host Conference Call and Webcast on August 11
- Taysha Gene Therapies and Catalent Expand Strategic Partnership to Include Future Commercial Manufacturing Support of TSHA-102 Gene Therapy for Rett Syndrome
- Taysha Gene Therapies (TSHA) is One of The Most Affordable Biotech Names to Invest In
- Taysha's R&D Chief Sold $1.2 Million in Stock After a 149% Run
- Taysha Gene Therapies Announces Multiple Presentations Highlighting its TSHA-102 Clinical Program at the 2026 IRSF Rett Syndrome Scientific Meeting
- Taysha Gene Therapies Announces Pricing of Public Offering of Common Stock and Pre-Funded Warrants
- Taysha Gene Therapies Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants
- Taysha Advances Rett Syndrome Programme as Pivotal Trial Enrollment Completes (TSHA)
- Taysha Gene Therapies Announces Completion of Dosing in REVEAL Pivotal Trial and Reports Longer-Term Clinical Data from Part A of REVEAL Phase 1/2 Trials Evaluating TSHA-102 for Rett Syndrome
中文標題是機器翻譯(NLLB 模型,不外送資料),專有名詞靠對照表,語意以英文原題為準。預設藏掉:選股文與自動生成站(Motley Fool、24/7 Wall St、Trefis、MarketBeat…)、加密幣、律師事務所的股東訴訟廣告、非英文、新聞稿裡的人事任命 / 出席活動 / 得獎、個人理財專欄,以及通路稿標題對不到上市公司的。個股標籤是從標題辨識的(通路標準寫法 (NASDAQ: NVDA)、公司名對照);帶「?」的是從摘要辨識、信心較低。來源等級 A / B / C 只影響精選排序,不是對媒體的評價。